A population-based study on serious inpatient bacterial infections in patients with chronic lymphocytic leukemia and their impact on survival

被引:3
|
作者
Steingrimsson, Vilhjalmur [1 ]
Gislason, Gauti K. [1 ]
Aspelund, Thor [2 ]
Turesson, Ingemar [3 ]
Bjorkholm, Magnus [4 ,5 ]
Landgren, Ola [6 ]
Kristinsson, Sigurdur Y. [1 ,4 ,5 ]
机构
[1] Univ Iceland, Fac Med, Sturlugata 8, IS-101 Reykjavik, Iceland
[2] Univ Iceland, Ctr Publ Hlth Sci, Reykjavik, Iceland
[3] Skane Univ Hosp, Dept Hematol & Coagulat Disorders, Malmo, Sweden
[4] Karolinska Univ Hosp, Dept Med, Stockholm, Sweden
[5] Karolinska Inst, Stockholm, Sweden
[6] Mem Sloan Kettering Canc Ctr, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA
基金
美国国家卫生研究院;
关键词
chronic lymphocytic leukemia; immunology and infectious diseases; lymphoproliferative diseases; BLOOD-STREAM INFECTIONS; MAJOR INFECTIONS; COMPLICATIONS; PATHOGENESIS; CHLORAMBUCIL; PROPHYLAXIS; FLUDARABINE; SPECTRUM; COHORT; RISK;
D O I
10.1111/ejh.13477
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Infections in chronic lymphocytic leukemia (CLL) have been thoroughly investigated in the setting of clinical trials and single-center studies. However, large cohort studies on real-world data and studies on temporal trends are lacking. We performed a nationwide study on serious bacterial infections in CLL. Methods Using high-quality Swedish government-based registries, 13 009 CLL patients diagnosed in 1982-2013 and their 49 380 matched controls were included. Results Overall, CLL patients had an increased risk of serious inpatient bacterial infections with a hazard ratio (HR) 5.32 and 95% confidence interval (95% CI) 5.11-5.53, and the highest risk was observed for septicemia (HR 6.91, 95% CI 6.46-7.39) and lung infections (5.91, 5.64-6.18). The risk of serious inpatient bacterial infections decreased overtime with HR 0.87 (0.81-0.94) and HR 0.76 (0.70-0.82) in 1993-2002 and 2003-2013, respectively, compared to 1982-1992. CLL patients had an increased risk of death following a serious inpatient bacterial infection compared to matched CLL patients, and the risk was highest in the first 12 months after the infection (HR 5.48, 95% CI 5.11-5.90). Conclusion We have, in this nationwide study, characterized the risk of serious bacterial infections in CLL patients and, importantly, depicted that the risk has decreased overtime.
引用
收藏
页码:547 / 554
页数:8
相关论文
共 50 条
  • [21] IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study
    Rotbain, Emelie Curovic
    Frederiksen, Henrik
    Hjalgrim, Henrik
    Rostgaard, Klaus
    Egholm, Gudrun Jakubsdottir
    Zahedi, Banafsheh
    Poulsen, Christian Bjorn
    Enggard, Lisbeth
    da Cunha-Bang, Caspar
    Niemann, Carsten Utoft
    HAEMATOLOGICA, 2020, 105 (06) : 1621 - 1629
  • [22] Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia
    Falchi, L.
    Vitale, C.
    Keating, M. J.
    Lerner, S.
    Wang, X.
    Gbito, K. Y. Elhor
    Strom, S.
    Wierda, W. G.
    Ferrajoli, A.
    ANNALS OF ONCOLOGY, 2016, 27 (06) : 1100 - 1106
  • [23] Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population-based study in the Netherlands, 1996-2020
    van der Straten, Lina
    Levin, Mark-David
    Dinnessen, Manette A. W.
    Visser, Otto
    Posthuma, Eduardus F. M.
    Doorduijn, Jeanette K.
    Langerak, Anton W.
    Kater, Arnon P.
    Dinmohamed, Avinash G.
    HEMASPHERE, 2024, 8 (11):
  • [24] Conditional survival to assess prognosis in patients with chronic lymphocytic leukemia
    Schlosser, Pascal
    Schiwitza, Annett
    Klaus, Jonas
    Hieke-Schulz, Stefanie
    Szic, Katarzyna Szarc vel
    Duyster, Justus
    Trepel, Martin
    Zirlik, Katja
    Schumacher, Martin
    Claus, Rainer
    ANNALS OF HEMATOLOGY, 2024, 103 (05) : 1613 - 1622
  • [25] Viral infections and their management in patients with chronic lymphocytic leukemia
    Melchardt, Thomas
    Weiss, Lukas
    Greil, Richard
    Egle, Alexander
    LEUKEMIA & LYMPHOMA, 2013, 54 (08) : 1602 - 1613
  • [26] Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada
    Huang, Steven J.
    Lee, Lauren J.
    Gerrie, Alina S.
    Gillan, Tanya L.
    Bruyere, Helene
    Hrynchak, Monica
    Smith, Adam C.
    Karsan, Aly
    Ramadan, Khaled M.
    Jayasundara, Kavisha S.
    Toze, Cynthia L.
    LEUKEMIA RESEARCH, 2017, 55 : 79 - 90
  • [27] Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma - Implications for clinical trials in this patient population
    Perkins, JG
    Flynn, JM
    Howard, RS
    Byrd, JC
    CANCER, 2002, 94 (07) : 2033 - 2039
  • [28] Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
    Mauro, Francesca Romana
    Giannarelli, Diana
    Visentin, Andrea
    Reda, Gianluigi
    Sportoletti, Paolo
    Frustaci, Anna Maria
    Chiarenza, Annalisa
    Ciolli, Stefania
    Vitale, Candida
    Laurenti, Luca
    De Paoli, Lorenzo
    Murru, Roberta
    Gentile, Massimo
    Rigolin, Gian Matteo
    Levato, Luciano
    Giordano, Annamaria
    Del Poeta, Giovanni
    Stelitano, Caterina
    Ielo, Claudia
    Noto, Alessandro
    Guarente, Valerio
    Molica, Stefano
    Coscia, Marta
    Tedeschi, Alessandra
    Gaidano, Gianluca
    Cuneo, Antonio
    Foa, Robin
    Martelli, Maurizio
    Girmenia, Corrado
    Gentile, Giuseppe
    Trentin, Livio
    CANCERS, 2021, 13 (13)
  • [29] Association between oral contraceptives and serious infections: A population-based cohort study
    Rosenthal, Yael Shalev
    Rosenthal, Adam
    Ram, Hila Shalev
    Ram, Shai
    Chodick, Gabriel
    Koren, Gideon
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (11) : 4241 - 4251
  • [30] Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials
    Gerrie, Alina S.
    Toze, Cynthia L.
    Ramadan, Khaled M.
    Li, Charles H.
    Sutherland, Judy
    Yee, Adrian
    Connors, Joseph M.
    LEUKEMIA & LYMPHOMA, 2012, 53 (01) : 77 - 82